Innovative Science

There is an urgent need for therapies to treat and prevent devastating viral diseases in immunocompromised patients who have limited or no treatment options.

We develop revolutionary, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies to treat patients fighting viral infections.

Step 1: Proprietary VST Profiling and Antigen Selection Process

‍

Step 2: Rapid and Scalable Off-the-Shelf VST Manufacturing

One manufacturing run from a single donor can generate hundreds of doses of VSTs.

Step 3: Cytomatch™ and Immediate Access to Our Allogeneic VST Therapies

‍

AlloVir’s Proprietary, Highly Efficient and Industrialized Platform Provides Key Advantages

The Heroic Role of T Cells Fighting Viral Infections

In healthy individuals, T cells from the body’s natural defense system provide protection against devastating viruses. For patients with T cell deficiencies, viruses may be uncontrolled, leading to potentially devastating and life-threatening consequences.

Developing An Immune System Outside the Body

T cells from healthy patients with the right characteristics are activated, expanded, and preserved for use on patients in need.

We Treat Individuals at High Risk

Our allogeneic, off-the-shelf VST candidates benefit patients with T cell deficiencies, including transplant recipients, immunocompromised cancer patients, the elderly, and the very young, who are at a higher risk of the devastating consequences of viral diseases.

BK Virus
Cytomegalovirus
Adenovirus
Epstein-Bar Virus

Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus

Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Human Herpesvirus-8

Bladder

Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy

Brain

Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy

Kidneys

Nephritis
Acute/chronic renal failure
End stage renal disease

Lungs

Pneumonia
Bronchitis
Respiratory failure

Eyes

Retinitis
Blindness

Liver

Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma

Small/Large Intestine

Colitis
Ulceration / perforation
Intestinal bleeding

Malignancy

Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the global leader in developing VST immunotherapies

We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses as treatment or prevention.

view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.

learn

Our People

We are united in purpose around a singular mission to prevent and defeat life-threatening viral diseases.

meet